Study of ESR1 gene changes in blood in advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have HR+ (hormone receptor-positive) and HER2-negative breast cancer that is advanced or has spread
- You are a candidate for a type of targeted therapy called a CDK4/6 inhibitor combined with hormone therapy
- You are willing to have a blood draw (liquid biopsy) before starting your first treatment for advanced disease
- You have not had hormone therapy for metastatic breast cancer before (unless it was as part of initial treatment after surgery)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
This trial tests an experimental oral drug (FWD1802) for women with a specific type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to hormone therapy. It looks at whether the drug can slow or stop cancer growth, especially if you have an ESR1 mutation.
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
This study is like a safety monitoring program for people with HR+/HER2- advanced breast cancer who are doing well on their first treatment (an aromatase inhibitor plus a CDK4/6 inhibitor). It uses simple blood tests every 3 months to look for ESR1 gene changes that could help guide future care.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.